ArticleScientific reports2026
Ensemble machine learning algorithms leveraged on serum proteomics for enhanced early detection of ovarian cancer.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
Ovarian cancer poses a significant clinical challenge due to its asymptomatic onset and poor prognosis, highlighting the critical need for effective early detection strategies. This study developed a framework that integrates serum proteomic profiling with machine learning algorithms. Serum samples from 188 patients and 208 healthy controls were analysed via Matrix-Assisted Laser Desorption/Ionization Time - of - Flight (MALDI - TOF) mass spectrometry, revealing 43 differentially expressed peptides (17 upregulated, 26 downregulated). An ensemble pipeline incorporating eight machine learning algorithms showed favorable discriminatory ability in the study cohort, with the area under the receiver operating characteristic curve (AUC) of the integrated models approaching 1.00 for distinguishing ovarian cancer samples from healthy controls. We identified three consensus biomarkers [mass-to-charge ratio (m/z) = 4211.41, 2881.50, 2662.15] through feature importance analysis, and their diagnostic reliability was supported by receiver operating characteristic curves optimization and decision curve analysis. Interpretability approaches integrating Shapley values and LIME indicated that the model's high performance (AUC ≈ 1) was driven by robust multi-dimensional feature contributions. Cross-referencing with existing datasets suggested the PDE11A as a potential diagnostic biomarker. Collectively, this ensemble machine learning algorithms leveraged on serum proteomics shows promising potential for early detection of ovarian cancer, offering a strategy to mitigate the limitations of single-analyte biomarkers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.